Instruction: The form may be signed by an executive officer of the registrant or
by any other duly  authorized  representative.  The name and title of the person
signing  the form  shall  be typed or  printed  beneath  the  signature.  If the
statement is signed on behalf of the registrant by an authorized  representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.

- -----------------------------------ATTENTION------------------------------------
    INTENTIONAL MISTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL
                        VIOLATIONS (SEE 18 U.S.C. 1001).
- --------------------------------------------------------------------------------




                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 12b-25                  SEC FILE NUMBER
                                                                    0-28128
                           NOTIFICATION OF LATE FILING          ---------------
                                                                 CUSIP NUMBER
                                                                   286171103

(Check One):  |_|Form 10-K |_|Form 20-F |_|Form 11-K |X|Form 10-Q |_|Form N-SAR

          For Period Ended:
          (   ) Transition Report on Form 10-K
          (   ) Transition Report on Form 20-F
          (   ) Transition Report on Form 11-K
          ( X ) Transition Report on Form 10-Q
          (   ) Transition Report on Form N-SAR
          For the Transition Period Ended: December 31, 1999
                                          --------------------------------------

         -------------------------------------------------------------
 Read Instructions (on back page) Before Preparing Form. Please Print or Type.
      NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION
                 HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.
         -------------------------------------------------------------

If the notification  relates to a portion of the filing checked above,  identify
the Item(s) to which the notification relates:

- --------------------------------------------------------------------------------

PART I -- REGISTRANT INFORMATION


Biorelease Corp.
- --------------------------------------------------------------------------------
Full Name of Registrants:


- --------------------------------------------------------------------------------
Former Name if Applicable


340 Granite Street, Suite 200
- --------------------------------------------------------------------------------
Address of Principal Executive Offices (Street and Number)


Manchester, NH 03102-4004
- --------------------------------------------------------------------------------
City, State and Zip Code




PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without  unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed (Check box if appropriate)
  _
 |_|   (a)  The reasons described in reasonable detail in Part III
            of this form could not be eliminated without
            unreasonable effort or expense;
  X    (b)  The subject quarterly report on Form 10-Q will be filed
            on or before the fifth calendar day following the
  _         prescribed due date; and
 |_|   (c)  The accountant's statement or other exhibit required by
            Rule 12(b)-25(c) has been attached if applicable.


PART III -- NARRATIVE

State  below in  reasonable  detail the  reasons  why the Form 10-Q could not be
filed within the prescribed time period. (Attach Extra Sheets If Needed)

"The  Company's  audit firm  requires  additional  time to review the  quarterly
financial statement for compliance before filing."


PART IV --OTHER INFORMATION

(1)  Name  and  telephone  number  of  person  to  contact  in  regard  to  this
     notification:

     R. Bruce Reeves                                                603 641-8443
     -------------------------------------------------------------  --- --------

(2)  Have all other periodic  reports  required under Section 13 or 15(d) of the
     Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
     of 1940 during the  preceding 12 months (or for such  shorter)  period that
     the registrant was required to file such reports) been filed?  If answer is
     no, identify report(s).                                          _
                                                             X  Yes  |_| No


(3)  Is it anticipated that any significant change in results of operations from
     the corresponding  period for the last fiscal year will be reflected by the
     earnings  statements  to be  included  in the  subject  report  or  portion
     thereof?                                                _
                                                            |_|  Yes   X  No

     If so, attach an explanation of the anticipated  change,  both  narratively
     and quantitatively, and, if appropriate, state the reasons why a reasonable
     estimate of the results cannot be made.

                                Biorelease Corp.
            -------------------------------------------------------
                  (Name of Registrant as Specified in Charter)

has  caused this  notification  to be signed on their behalf by the  undersigned
hereunto duly authorized.


Date February 15, 1999                By /s/ R. Bruce Reeves
     ---------------------------         ---------------------------------------
                                         R. Bruce Reeves, President